Search results
Results from the WOW.Com Content Network
The Potter's House Church said in a statement that Bishop T.D. Jakes is stable and under the care of healthcare professionals. Texas megachurch pastor T.D. Jakes suffers health incident after ...
Dallas, Texas megachurch pastor Bishop T.D. Jakes spoke remotely to his congregation Sunday, one week after he suffered a health-scare during a sermon.
Bishop T.D. Jakes, 67, had what his church described as a "slight health incident" during a sermon Sunday.. The megachurch celebrity pastor was seen to pause his sermon and shake as people ...
Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or (in the United States) Lou Gehrig's disease (LGD), is a rare, terminal neurodegenerative disorder that results in the progressive loss of both upper and lower motor neurons that normally control voluntary muscle contraction. [3]
Astrophysicist Stephen Hawking, whose ALS was diagnosed in 1963, had the disease for 55 years, the longest recorded time one had the disease. He died at the age of 76 in 2018. The 11th century monk Hermann of Reichenau had a lifelong disease that is considered likely to have been ALS. This would make him one of the earliest known patients of ...
Amyotrophic lateral sclerosis, ALS [6] (Lou Gehrig's disease) 335.20 G12.21 Parkinson's disease (Primary or Idiopathic Parkinsonism) 332 G20 Secondary Parkinsonism: G21 Parkinson plus syndromes: Pantothenate kinase-associated neurodegeneration: G23.0 Progressive Supranuclear Ophthalmoplegia: G23.1 Striatonigral degeneration: G23.2 Multiple ...
Bishop TD Jakes is in stable condition a day after suffering a medical emergency during a sermon — but the mega-church pastor is facing another hurdle related to sex abuse allegations.. Jakes ...
The institute has raised and spent more than $100 million on research into effective treatments for ALS and practices open-source science. [19] After the discovery that the multiple sclerosis drug Gilenya might also be a treatment for ALS, the Institute enrolled 30 people in a Phase 2A clinical trial the drug in 2013, though it did not progress further.